3.34
전일 마감가:
$3.68
열려 있는:
$3.67
하루 거래량:
1.73M
Relative Volume:
2.73
시가총액:
$113.59M
수익:
$160.43M
순이익/손실:
$-227.64M
주가수익비율:
-0.0486
EPS:
-68.77
순현금흐름:
$-170.79M
1주 성능:
-14.58%
1개월 성능:
-10.22%
6개월 성능:
-47.48%
1년 성능:
+6.03%
아제너스 Stock (AGEN) Company Profile
명칭
Agenus Inc
전화
781-674-4410
주소
3 FORBES ROAD, LEXINGTON, MA
AGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
AGEN
Agenus Inc
|
3.34 | 125.15M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
아제너스 Stock (AGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | 개시 | Robert W. Baird | Outperform |
| 2023-02-28 | 재개 | H.C. Wainwright | Buy |
| 2022-09-28 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-04-22 | 개시 | B. Riley FBR | Buy |
| 2016-10-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | 재확인 | Maxim Group | Buy |
| 2016-03-11 | 업그레이드 | Maxim Group | Hold → Buy |
| 2015-12-16 | 개시 | Jefferies | Buy |
| 2015-10-27 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-07-27 | 재확인 | MLV & Co | Buy |
| 2015-06-11 | 개시 | Oppenheimer | Outperform |
| 2015-01-12 | 재확인 | Maxim Group | Buy |
| 2015-01-09 | 재확인 | MLV & Co | Buy |
| 2015-01-09 | 재확인 | Maxim Group | Buy |
| 2014-12-19 | 재확인 | Maxim Group | Buy |
| 2014-05-08 | 재확인 | Maxim Group | Buy |
| 2014-03-14 | 재확인 | MLV & Co | Buy |
| 2013-10-08 | 재확인 | Maxim Group | Buy |
| 2012-01-05 | 개시 | William Blair | Outperform |
| 2011-12-01 | 개시 | Global Hunter Securities | Buy |
모두보기
아제너스 주식(AGEN)의 최신 뉴스
Agenus (AGEN) Q1 2025 Earnings Call Transcript - AOL.com
Agenus Forms Major Strategic Collaboration with Zydus Lifesciences - TipRanks
Agenus Announces the Closing of $141M Strategic Collaboration with Zydus Group - Oncodaily
Institution Moves: Will BHRPRD announce a stock splitPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal - Pharmaceutical Technology
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - 뉴스와이어
Agenus closes strategic collaboration with Zydus Lifesciences By Investing.com - Investing.com Nigeria
Zydus LifeSciences Acquires Biologics Manufacturing Facilities from Agenus - Contract Pharma
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences - BioPharm International
Agenus Falls After $141 Million Zydus Deal Closes - marketscreener.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Zydus Completes Agenus Biologics Facilities Acquisition And Launches U.S. CDMO Unit - Pulse 2.0
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - StreetInsider
New Zylidac Bio sites help secure U.S. biologic drug supply chains - Stock Titan
AGENAgenus Latest Stock News & Market Updates - Stock Titan
Agenus closes strategic collaboration with Zydus Lifesciences - Investing.com
Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing - scanx.trade
Cancer combo shows 42% 2yr survival as $141M immunotherapy deal closes - Stock Titan
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer - Investing.com Nigeria
Agenus appoints CEO Garo Armen as interim CFO and names new accounting officer By Investing.com - Investing.com South Africa
Agenus Consolidates Financial Leadership With Interim CFO Appointment - TipRanks
Agenus Inc. Appoints Austin Charette as Principal Accounting Officer, Effective January 8, 2026 - marketscreener.com
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas - 뉴스와이어
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
About Us - FinancialContent
AGEN Stock Price, Forecast & Analysis | AGENUS INC (NASDAQ:AGEN) - Chartmill
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Why Agenus Inc. stock is a must watch in 20252025 Geopolitical Influence & Reliable Price Breakout Alerts - Улправда
What risks investors should watch in Agenus Inc. stockEarnings Overview Summary & Daily Stock Trend Reports - Улправда
Is Agenus Inc. stock attractive for income investorsNew Guidance & Low Risk Entry Point Guides - Улправда
Will Agenus Inc. stock sustain high P E ratiosJuly 2025 Setups & Community Verified Swing Trade Signals - Улправда
Agenus amends Ligand agreement, modifies warrant holder rights - TipRanks
How geopolitical tensions affect Agenus Inc. stockMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Is Agenus Inc. stock a good choice for value investorsEarnings Forecast Updates & Outstanding Growth Stocks - ulpravda.ru
What valuation multiples suggest for Agenus Inc. stockHead and Shoulders Patterns & Superior Portfolio Investment - ulpravda.ru
Aug Summary: Is Agenus Inc stock attractive for income investorsWeekly Risk Report & Stepwise Entry and Exit Trade Signals - Bộ Nội Vụ
Agenus (AGEN) Q4 2024 Earnings Call Transcript - AOL.com
Agenus (AGEN) Q3 2024 Earnings Call Transcript - The Motley Fool
Is Agenus Inc a good long term investmentRSI Overbought/Oversold & Learn the Basics of Investing in 5 Days - earlytimes.in
H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN
Agenus (AGEN) CEO Garo Armen Takes 4,942 Shares as Salary Payment - Stock Titan
Short Interest in Agenus Inc. (NASDAQ:AGEN) Rises By 56.5% - MarketBeat
Agenus publishes C-800-01 trial data in The Journal for Immunotherapy of Cancer - MSN
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC - BioSpace
Agenus reports positive results for cancer immunotherapy in ovarian cancer By Investing.com - Investing.com Nigeria
Agenus Inc AJ8 Stock Analysis and ForecastVolume Analysis Techniques & High Return Investment Ideas - earlytimes.in
Botensilimab + Balstilimab in Refractory MSS mCRC: Insights from an ESMO AnalysisAgenus - Oncodaily
Agenus publishes C-800-01 trial data in The Journal for ImmunoTherapy of Cancer - TipRanks
Agenus reports positive results for cancer immunotherapy in ovarian cancer - Investing.com India
아제너스 (AGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):